Doximity's Op-Med
Op-Med serves as a platform for Doximity members to share their personal narratives and insights. The views shared in this space belong to the individual authors and may not reflect Doximity's official stance. Please note that the content provided is not intended to replace professional medical advice.
Outlet metrics
Global
N/A
Country
N/A
Category
N/A
Articles
-
3 days ago |
opmed.doximity.com | Stephanie Wottrich |Roxanne Nelson
Last week I was in clinic, and I saw a patient who I had met virtually once before. She had been seen by other residents that came before me in our small fiber neuropathy clinic and had been through an extensive workup where she was diagnosed with small fiber neuropathy after a skin biopsy.
-
3 days ago |
opmed.doximity.com | Roxanne Nelson |Christina Brown
A systematic assessment of colorectal cancer (CRC) screening status in a large diverse population, that included a mailed fecal immunochemical testing (FIT), approximately doubled the screening up-to-date status among all patients, according to new research presented at Digestive Disease Week 2025.
-
3 days ago |
opmed.doximity.com | Roxanne Nelson |Christina Brown
Epigenic markers detected in umbilical cord blood at birth could signify risk for metabolic disease and increased liver fat over the course of a lifespan, according to research presented at Digestive Disease Week 2025. “If these DNA markers are confirmed in larger studies, they could help doctors spot health risks earlier, maybe even at birth,” said lead author Ashley Jowell, MD, a resident physician in internal medicine at Duke University Health System.
-
3 days ago |
opmed.doximity.com | Roxanne Nelson |Christina Brown
Researchers have identified pathogenic variants in 4 genes that are independent risk factors for worse survival in gastric cancer. These findings could potentially pave the way for precision oncology and targeted therapies, according to a study presented at Digestive Disease Week 2025.
-
1 week ago |
opmed.doximity.com | Roxanne Nelson
A non-invasive urine test could help prevent unnecessary and repeat biopsies without a digital rectal exam (DRE) in men with elevated prostate-specific antigen (PSA) levels, according to new research presented at the annual meeting of the American Urological Society. The urinary 18-gene MyProstateScore 2.0 (MPS2) provided high sensitivity for the detection of clinically significant prostate cancer. while ruling out 37%-42% of unnecessary biopsies for men undergoing an initial biopsy.
Doximity's Op-Med journalists
Contact details
No sites or socials found.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →